List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/918860/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis. American Journal of Hematology, 2022, 97, 90-98.	4.1	13
2	Cell-Mediated Immune Responses After Administration of the Live or the Recombinant Zoster Vaccine: 5-Year Persistence. Journal of Infectious Diseases, 2022, 225, 1477-1481.	4.0	11
3	Immunogenicity of Conjugated and Polysaccharide Pneumococcal Vaccines Administered During Pregnancy or Postpartum to Women With HIV. Journal of Infectious Diseases, 2022, 225, 1021-1031.	4.0	3
4	Effect of Maternal Immunization With 10-Valent Pneumococcus Conjugate Vaccine (PCV-10), 23-Valent Pneumococcus Polysaccharide Vaccine, or Placebo on the Immunogenicity of PCV-10 in Human Immunodeficiency Virus–Exposed Uninfected Infants: A Randomized Clinical Trial. Clinical Infectious Diseases, 2022, 75, 996-1005.	5.8	4
5	Coordination of inflammatory responses in children with perinatally-acquired HIV infection. Aids, 2022, Publish Ahead of Print, .	2.2	2
6	Transcriptional and Immunologic Correlates of Response to Pandemic Influenza Vaccine in Aviremic, HIV-Infected Children. Frontiers in Immunology, 2021, 12, 639358.	4.8	2
7	Plasma biomarker factors associated with neurodevelopmental outcomes in children with perinatal HIV infection and controlled viremia. Aids, 2021, 35, 1375-1384.	2.2	7
8	Comparative Antibody Responses to the Live-Attenuated and Recombinant Herpes Zoster Vaccines. Journal of Virology, 2021, 95, .	3.4	18
9	Immunologic and Virologic Factors Associated With Hospitalization in Human Immunodeficiency Virus–Exposed, Uninfected Infants in the United States. Clinical Infectious Diseases, 2021, 73, 1089-1096.	5.8	21
10	Safety, immunogenicity, and transplacental antibody transport of conjugated and polysaccharide pneumococcal vaccines administered to pregnant women with HIV: a multicentre randomised controlled trial. Lancet HIV,the, 2021, 8, e408-e419.	4.7	9
11	Site-Randomized Controlled Trial of a Combined Cognitive Behavioral Therapy and a Medication Management Algorithm for Treatment of Depression Among Youth Living With HIV in the United States. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 88, 497-505.	2.1	3
12	Pharmacokinetics of tenofovir alafenamide with and without cobicistat in pregnant and postpartum women living with HIV. Aids, 2021, 35, 407-417.	2.2	15
13	Immune Responses to Varicella-Zoster Virus Vaccines. Current Topics in Microbiology and Immunology, 2021, , 223-246.	1.1	3
14	Adjuvanted Recombinant Glycoprotein E Herpes Zoster Vaccine. Clinical Infectious Diseases, 2020, 70, 1509-1515.	5.8	12
15	Letermovir prophylaxis through day 100 post transplant is safe and effective compared with alternative CMV prophylaxis strategies following adult cord blood and haploidentical cord blood transplantation. Bone Marrow Transplantation, 2020, 55, 780-786.	2.4	31
16	Human Immunodeficiency Virus Exposure but Not Early Cytomegalovirus Infection Is Associated With Increased Hospitalization and Decreased Memory T-Cell Responses to Tetanus Vaccine. Journal of Infectious Diseases, 2020, 221, 1167-1175.	4.0	7
17	Immunogenicity and safety of different dosing schedules of trivalent inactivated influenza vaccine in pregnant women with HIV: a randomised controlled trial. Lancet HIV,the, 2020, 7, e91-e103.	4.7	16
18	Effects of Pregnancy and Isoniazid Preventive Therapy on Mycobacterium tuberculosis Interferon Gamma Response Assays in Women With HIV. Clinical Infectious Diseases, 2020, 73, e3555-e3562.	5.8	9

#	Article	IF	CITATIONS
19	Lower influenza-specific cell-mediated immune responses in individuals with atopic dermatitis compared with healthy controls. Human Vaccines and Immunotherapeutics, 2020, 16, 2727-2735.	3.3	2
20	Understanding the mechanism of action of cytomegalovirus-induced regulatory T cells. Virology, 2020, 547, 1-6.	2.4	12
21	Immune Correlates of Herpes Zoster in People Living with HIV on Effective Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2019, 35, 890-895.	1.1	3
22	Immune responses to zoster vaccines. Human Vaccines and Immunotherapeutics, 2019, 15, 772-777.	3.3	28
23	The Effect of Age on the Immunogenicity of the Live Attenuated Zoster Vaccine Is Predicted by Baseline Regulatory T Cells and Varicella-Zoster Virus-Specific T Cell Immunity. Journal of Virology, 2019, 93, .	3.4	18
24	What can we learn about influenza infection and vaccination from transcriptomics?. Human Vaccines and Immunotherapeutics, 2019, 15, 2615-2623.	3.3	6
25	Antibody and B cell responses to an investigational adjuvanted RSV vaccine for older adults. Human Vaccines and Immunotherapeutics, 2019, 15, 2466-2474.	3.3	5
26	HIV-exposed-uninfected infants have increased inflammation and monocyte activation. Aids, 2019, 33, 845-853.	2.2	54
27	Brief Report: Markers of Spontaneous Preterm Delivery in Women Living With HIV: Relationship With Protease Inhibitors and Vitamin D. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 82, 181-187.	2.1	2
28	Persistence of Varicella-Zoster Virus Cell-Mediated Immunity After the Administration of a Second Dose of Live Herpes Zoster Vaccine. Journal of Infectious Diseases, 2019, 219, 335-338.	4.0	19
29	Factors Associated with Lower Respiratory Tract Infections in HIV-Exposed Uninfected Infants. AIDS Research and Human Retroviruses, 2018, 34, 527-535.	1.1	15
30	Persistence of memory B-cell and T-cell responses to the quadrivalent HPV vaccine in HIV-infected children. Aids, 2018, 32, 851-860.	2.2	14
31	Varicella-Zoster Virus DNA in Blood After Administration of Herpes Zoster Vaccine. Journal of Infectious Diseases, 2018, 217, 1055-1059.	4.0	8
32	2027. Immune Correlates of Protection Against Herpes Zoster (HZ) in People Living with HIV (PLWH). Open Forum Infectious Diseases, 2018, 5, S590-S591.	0.9	0
33	2572. Decreased T-Cell Response, but Appropriate Antibody Production to Tetanus Vaccine Among HIV-Exposed Uninfected Infants in Botswana. Open Forum Infectious Diseases, 2018, 5, S75-S75.	0.9	Ο
34	Herpes Zoster and Herpes Zoster Vaccine Rates Among Adults Living With and Without HIV in the Veterans Aging Cohort Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 79, 527-533.	2.1	7
35	Neutralization and hemagglutination-inhibition antibodies following influenza vaccination of HIV-infected and HIV-uninfected pregnant women. PLoS ONE, 2018, 13, e0210124.	2.5	13
36	Comparative Immune Responses to Licensed Herpes Zoster Vaccines. Journal of Infectious Diseases, 2018, 218, S81-S87.	4.0	31

#	Article	IF	CITATIONS
37	B and T Cell Phenotypic Profiles of African HIV-Infected and HIV-Exposed Uninfected Infants: Associations with Antibody Responses to the Pentavalent Rotavirus Vaccine. Frontiers in Immunology, 2018, 8, 2002.	4.8	11
38	Th1 memory differentiates recombinant from live herpes zoster vaccines. Journal of Clinical Investigation, 2018, 128, 4429-4440.	8.2	63
39	The Neonatal Immune System: General Concepts and Clinical Correlations. Current Immunology Reviews, 2018, 13, .	1.2	0
40	A clinical trial of intradermal and intramuscular seasonal influenza vaccination in patients with atopic dermatitis. Journal of Allergy and Clinical Immunology, 2017, 139, 1575-1582.e8.	2.9	11
41	Four-year persistence of type-specific immunity after quadrivalent human papillomavirus vaccination in HIV-infected children: Effect of a fourth dose of vaccine. Vaccine, 2017, 35, 1712-1720.	3.8	25
42	Metabolic Phenotypes of Response to Vaccination in Humans. Cell, 2017, 169, 862-877.e17.	28.9	234
43	Efficacy of Maternal Influenza Vaccination Against All-Cause Lower Respiratory Tract Infection Hospitalizations in Young Infants: Results From a Randomized Controlled Trial. Clinical Infectious Diseases, 2017, 65, 1066-1071.	5.8	65
44	Varicella-Zoster Virus–Specific Cellular Immune Responses to the Live Attenuated Zoster Vaccine in Young and Older Adults. Journal of Immunology, 2017, 199, 604-612.	0.8	33
45	Excess respiratory viral infections and low antibody responses among HIV-exposed, uninfected infants. Aids, 2017, 31, 669-679.	2.2	33
46	Studies with herpes zoster vaccines in immune compromised patients. Expert Review of Vaccines, 2017, 16, 1217-1230.	4.4	21
47	Inflammation and Immune Activation in Antiretroviral-Treated Human Immunodeficiency Virus Type 1–Infected African Infants and Rotavirus Vaccine Responses. Journal of Infectious Diseases, 2017, 215, 928-932.	4.0	13
48	Arm Paralysis After Routine Childhood Vaccinations: Application of Advanced Molecular Methods to the Causality Assessment of an Adverse Event After Immunization. Journal of the Pediatric Infectious Diseases Society, 2017, 6, e161-e164.	1.3	4
49	Immune Senescence Factors Associated with the Immunogenicity of a Live Attenuated Zoster Vaccine (ZV) in Older Adults. Open Forum Infectious Diseases, 2017, 4, S413-S414.	0.9	2
50	Altered Natural Killer Cell Function in HIV-Exposed Uninfected Infants. Frontiers in Immunology, 2017, 8, 470.	4.8	23
51	Contribution of Serologic Assays in the Evaluation of Influenza Virus Infection Rates and Vaccine Efficacy in Pregnant Women: Report From Randomized Controlled Trials. Clinical Infectious Diseases, 2017, 64, 1773-1779.	5.8	12
52	Cytomegalovirus infection in HIV-infected and uninfected individuals is characterized by circulating regulatory T cells of unconstrained antigenic specificity. PLoS ONE, 2017, 12, e0180691.	2.5	7
53	Antiretroviral Resistance and Pregnancy Characteristics of Women with Perinatal and Nonperinatal HIV Infection. Infectious Diseases in Obstetrics and Gynecology, 2016, 2016, 1-8.	1.5	8
54	Maternal Lopinavir/Ritonavir Is Associated with Fewer Adverse Events in Infants than Nelfinavir or Atazanavir. Infectious Diseases in Obstetrics and Gynecology, 2016, 2016, 1-9.	1.5	4

#	Article	IF	CITATIONS
55	Immune Responses to Circulating and Vaccine Viral Strains in HIV-Infected and Uninfected Children and Youth Who Received the 2013/2014 Quadrivalent Live-Attenuated Influenza Vaccine. Frontiers in Immunology, 2016, 7, 142.	4.8	3
56	Effect of Depot Medoxyprogesterone Acetate on Immune Functions and Inflammatory Markers of HIV-Infected Women. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, 137-145.	2.1	4
57	Duration of Infant Protection Against Influenza Illness Conferred by Maternal Immunization. JAMA Pediatrics, 2016, 170, 840.	6.2	99
58	Herpes Simplex Virus and Varicella-Zoster Virus. Microbiology Spectrum, 2016, 4, .	3.0	31
59	Immune response and reactogenicity of intradermal administration versus subcutaneous administration of varicella-zoster virus vaccine: an exploratory, randomised, partly blinded trial. Lancet Infectious Diseases, The, 2016, 16, 915-922.	9.1	38
60	Antibody responses to influenza a H1N1 vaccine compared to the circulating strain in influenza vaccine recipients during the 2013/2014 season in North America. Journal of Clinical Virology, 2016, 83, 56-60.	3.1	1
61	Regulatory T Cells in Infections: Getting It Just Right. Journal of Infectious Diseases, 2016, 214, 4-5.	4.0	2
62	Influenza vaccination of pregnant women protects them over two consecutive influenza seasons in a randomized controlled trial. Expert Review of Vaccines, 2016, 15, 1055-1062.	4.4	20
63	Cellular and Humoral Responses to a Second Dose of Herpes Zoster Vaccine Administered 10 Years After the First Dose Among Older Adults. Journal of Infectious Diseases, 2016, 213, 14-22.	4.0	69
64	Characterization of Functional Antibody and Memory B-Cell Responses to pH1N1 Monovalent Vaccine in HIV-Infected Children and Youth. PLoS ONE, 2015, 10, e0118567.	2.5	15
65	Determinants of Vaccine Immunogenicity in HIV-Infected Pregnant Women: Analysis of B and T Cell Responses to Pandemic H1N1 Monovalent Vaccine. PLoS ONE, 2015, 10, e0122431.	2.5	18
66	Physical Function Impairment of Older, HIV-Infected Adults Is Associated with Cytomegalovirus Immunoglobulin Response. AIDS Research and Human Retroviruses, 2015, 31, 905-912.	1.1	21
67	Kinetics of Hemagglutination-Inhibiting Antibodies Following Maternal Influenza Vaccination Among Mothers With and Those Without HIV Infection and Their Infants. Journal of Infectious Diseases, 2015, 212, 1976-1987.	4.0	62
68	Heterogeneity of T Cell Responses to Pandemic pH1N1 Monovalent Vaccine in HIV-Infected Pregnant Women. AIDS Research and Human Retroviruses, 2015, 31, 1170-1177.	1.1	1
69	Safety, immunogenicity and shedding of LAIV4 in HIV-infected and uninfected children. Vaccine, 2015, 33, 4790-4797.	3.8	14
70	Serious Adverse Events Are Uncommon with Combination Neonatal Antiretroviral Prophylaxis: A Retrospective Case Review. PLoS ONE, 2015, 10, e0127062.	2.5	11
71	Broadly Reactive Human CD8 T Cells that Recognize an Epitope Conserved between VZV, HSV and EBV. PLoS Pathogens, 2014, 10, e1004008.	4.7	36
72	Cell-mediated immune responses to respiratory syncytial virus infection. Human Vaccines and Immunotherapeutics, 2014, 10, 1047-1056.	3.3	12

#	Article	IF	CITATIONS
73	Influenza Vaccination of Pregnant Women and Protection of Their Infants. New England Journal of Medicine, 2014, 371, 918-931.	27.0	463
74	Regulatory T Cells and the Risk of CMV End-Organ Disease in Patients With AIDS. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 66, 25-32.	2.1	7
75	Epstein-Barr and Other Herpesvirus Infections in Patients With Early Onset Type 1 Diabetes Treated With Daclizumab and Mycophenolate Mofetil. Clinical Infectious Diseases, 2013, 56, 248-254.	5.8	17
76	Effect of abatacept on immunogenicity of vaccines in individuals with type 1 diabetes. Vaccine, 2013, 31, 4791-4794.	3.8	7
77	Reactivation of latent viruses in individuals receiving rituximab for new onset type 1 diabetes. Journal of Clinical Virology, 2013, 57, 115-119.	3.1	24
78	Efficacy and immunogenicity of influenza vaccine in HIV-infected children. Aids, 2013, 27, 369-379.	2.2	37
79	Immunogenicity of Licensed Influenza A (H1N1) 2009 Monovalent Vaccines in HIV-Infected Children and Youth. Journal of the Pediatric Infectious Diseases Society, 2013, 2, 352-360.	1.3	10
80	High proportions of regulatory B and T cells are associated with decreased cellular responses to pH1N1 influenza vaccine in HIV-infected children and youth (IMPAACT P1088). Human Vaccines and Immunotherapeutics, 2013, 9, 957-968.	3.3	15
81	Safety and Immunogenicity of 2009 pH1N1 Vaccination in HIV-Infected Pregnant Women. Clinical Infectious Diseases, 2013, 56, 1488-1497.	5.8	30
82	Varicella Zoster Virus-Specific Immune Responses to a Herpes Zoster Vaccine in Elderly Recipients With Major Depression and the Impact of Antidepressant Medications. Clinical Infectious Diseases, 2013, 56, 1085-1093.	5.8	69
83	Immune Correlates of Herpes Zoster in HIV-Infected Children and Youth. Journal of Virology, 2012, 86, 2878-2881.	3.4	20
84	Safety and Immunogenicity of 2009 Pandemic H1N1 Influenza Vaccination in Perinatally HIV-1-Infected Children, Adolescents, and Young Adults. Journal of Infectious Diseases, 2012, 206, 421-430.	4.0	24
85	Humoral, Mucosal, and Cell-Mediated Immunity Against Vaccine and Nonvaccine Genotypes After Administration of Quadrivalent Human Papillomavirus Vaccine to HIV-Infected Children. Journal of Infectious Diseases, 2012, 206, 1309-1318.	4.0	57
86	Responses to Hepatitis A Virus Vaccine in HIV-Infected Women. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 60, e15-e18.	2.1	4
87	Pandemic Influenza A H1N1 2009 Infection versus Vaccination: A Cohort Study Comparing Immune Responses in Pregnancy. PLoS ONE, 2012, 7, e33048.	2.5	26
88	Human atopic dermatitis complicated by eczema herpeticum is associated with abnormalities in IFN-Î <sup>3</sup> response. Journal of Allergy and Clinical Immunology, 2011, 127, 965-973.e5.	2.9	125
89	Effect of rituximab on human inÂvivo antibody immune responses. Journal of Allergy and Clinical Immunology, 2011, 128, 1295-1302.e5.	2.9	91
90	Major depressive disorder and immunity to varicella-zoster virus in the elderly. Brain, Behavior, and Immunity, 2011, 25, 759-766.	4.1	74

#	Article	IF	CITATIONS
91	Lytic and latent EBV gene expression in transplant recipients with and without post-transplant lymphoproliferative disorder. Journal of Clinical Virology, 2011, 52, 231-235.	3.1	18
92	Reduced immunogenicity of influenza vaccines in HIV-infected compared with uninfected pregnant women is associated with regulatory T cells. Aids, 2011, 25, 595-602.	2.2	31
93	Effect of menstrual cycle variation in female sex hormones on cellular immunity and regulation. Journal of Reproductive Immunology, 2011, 89, 70-77.	1.9	35
94	Cytotoxicity of glioblastoma cells mediated ex vivo by varicella-zoster virus-specific T cells. Journal of NeuroVirology, 2011, 17, 448-54.	2.1	6
95	Respiratory Viral Infections. Seminars in Respiratory and Critical Care Medicine, 2011, 32, 371-372.	2.1	2
96	Safety and Tolerability of Antiretrovirals during Pregnancy. Infectious Diseases in Obstetrics and Gynecology, 2011, 2011, 1-6.	1.5	16
97	Dynamics of Regulatory T-Cells during Pregnancy: Effect of HIV Infection and Correlations with Other Immune Parameters. PLoS ONE, 2011, 6, e28172.	2.5	27
98	Anti-Influenza Serum and Mucosal Antibody Responses After Administration of Live Attenuated or Inactivated Influenza Vaccines to HIV-Infected Children. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 55, 189-196.	2.1	41
99	Optimization of storage and shipment of cryopreserved peripheral blood mononuclear cells from HIV-infected and uninfected individuals for ELISPOT assays. Journal of Immunological Methods, 2010, 363, 42-50.	1.4	57
100	Regulatory function of cytomegalovirus-specific CD4+CD27â^'CD28â^' T cells. Virology, 2010, 398, 158-167.	2.4	39
101	Influence of Age and Nature of Primary Infection on Varicellaâ€Zoster Virus–Specific Cellâ€Mediated Immune Responses. Journal of Infectious Diseases, 2010, 201, 1024-1030.	4.0	110
102	T Cell Responses of HIV-Infected Children after Administration of Inactivated or Live Attenuated Influenza Vaccines. AIDS Research and Human Retroviruses, 2010, 26, 51-59.	1.1	10
103	Safety and Immunogenicity of a Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Vaccine in HIV-Infected Children 7 to 12 Years Old. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 55, 197-204.	2.1	168
104	VZV T Cell-Mediated Immunity. Current Topics in Microbiology and Immunology, 2010, 342, 341-357.	1.1	164
105	Safety and immunogenicity of a live attenuated varicella vaccine in VZV-seropositive HIV-infected adults. Hum Vaccin, 2010, 6, 318-321.	2.4	49
106	Kinetics and Determining Factors of the Virologic Response to Antiretrovirals during Pregnancy. Infectious Diseases in Obstetrics and Gynecology, 2009, 2009, 1-8.	1.5	15
107	Optimization and Limitations of Use of Cryopreserved Peripheral Blood Mononuclear Cells for Functional and Phenotypic T-Cell Characterization. Vaccine Journal, 2009, 16, 1176-1186.	3.1	164
108	Varicellaâ€Zoster Virus–Specific Immune Responses to Herpes Zoster in Elderly Participants in a Trial of a Clinically Effective Zoster Vaccine. Journal of Infectious Diseases, 2009, 200, 1068-1077.	4.0	244

#	Article	IF	CITATIONS
109	Kinetics of viral shedding and immune responses in adults following administration of cold-adapted influenza vaccine. Vaccine, 2009, 27, 7359-7366.	3.8	26
110	Resistance to antiretrovirals in HIV-infected pregnant women. Journal of Clinical Virology, 2009, 45, 39-42.	3.1	36
111	Virologic and Immunologic Correlates With the Magnitude of Antibody Responses to the Hepatitis A Vaccine in HIV-Infected Children on Highly Active Antiretroviral Treatment. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 52, 17-24.	2.1	37
112	A PHASE I–II STUDY OF LIVE ATTENUATED VARICELLA-ZOSTER VIRUS VACCINE TO BOOST IMMUNITY IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED CHILDREN WITH PREVIOUS VARICELLA. Pediatric Infectious Disease Journal, 2009, 28, 653-655.	2.0	37
113	Shedding of live vaccine virus, comparative safety, and influenza-specific antibody responses after administration of live attenuated and inactivated trivalent influenza vaccines to HIV-infected children. Vaccine, 2008, 26, 4210-4217.	3.8	84
114	Continuous improvement in the immune system of HIV-infected children on prolonged antiretroviral therapy. Aids, 2008, 22, 2267-2277.	2.2	30
115	Impaired Immunity to Recall Antigens and Neoantigens in Severely Immunocompromised Children and Adolescents during the First Year of Effective Highly Active Antiretroviral Therapy. Journal of Infectious Diseases, 2008, 198, 1123-1130.	4.0	39
116	Quality Assurance Program for Peripheral Blood Mononuclear Cell Cryopreservation. Vaccine Journal, 2007, 14, 1242-1244.	3.1	24
117	Ex Vivo Effect of Estrogen and Progesterone Compared With Dexamethasone on Cell-Mediated Immunity of HIV-Infected and Uninfected Subjects. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 45, 137-143.	2.1	28
118	Phenotypic and functional characterization of ex vivo T cell responses to the live attenuated herpes zoster vaccine. Vaccine, 2007, 25, 7087-7093.	3.8	42
119	Factors that affect in vitro measurement of the susceptibility of herpes simplex virus to nucleoside analogues. Journal of Clinical Virology, 2007, 38, 139-145.	3.1	19
120	Cytomegalovirus-Specific Cell-Mediated Immunity in HIV-Infected Children on HAART. AIDS Research and Human Retroviruses, 2006, 22, 283-288.	1.1	12
121	Regulatory T cells generated during cytomegalovirus in vitro stimulation of mononuclear cells from HIV-infected individuals on HAART correlate with decreased lymphocyte proliferation. Virology, 2006, 352, 408-417.	2.4	13
122	Administration of Live Varicella Vaccine to HIVâ€Infected Children with Current or Past Significant Depression of CD4+T Cells. Journal of Infectious Diseases, 2006, 194, 247-255.	4.0	123
123	Antibody Responses to Hepatitis A Virus Vaccine in HIVâ€Infected Children with Evidence of Immunologic Reconstitution while Receiving Highly Active Antiretroviral Therapy. Journal of Infectious Diseases, 2006, 193, 302-311.	4.0	96
124	Cytomegalovirusâ€Specific Immunity and Protection against Viremia and Disease in HIVâ€Infected Patients in the Era of Highly Active Antiretroviral Therapy. Journal of Infectious Diseases, 2006, 193, 488-493.	4.0	27
125	Cytomegalovirus Viremia, Mortality, and End-Organ Disease Among Patients With AIDS Receiving Potent Antiretroviral Therapies. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 38, 538-544.	2.1	68
126	History of Chickenpox and Shingles and Prevalence of Antibodies to Varicella-Zoster Virus and Three Other Herpesviruses among Adults with Glioma and Controls. American Journal of Epidemiology, 2005, 161, 929-938.	3.4	68

#	Article	IF	CITATIONS
127	Evaluation of Three Immunoassay Kits for Rapid Detection of Influenza Virus A and B. Vaccine Journal, 2005, 12, 367-370.	3.1	78
128	Dual Infections of the Central Nervous System with Epsteinâ€Barr Virus. Journal of Infectious Diseases, 2005, 191, 234-237.	4.0	101
129	Risk of transmission of herpesviruses through cord blood transplantation. Biology of Blood and Marrow Transplantation, 2005, 11, 35-38.	2.0	18
130	Human Herpesviruses 6 and 7 and Central Nervous System Infection in Children <sup>1</sup> . Emerging Infectious Diseases, 2004, 10, 1450-1454.	4.3	33
131	Antimicrobial-Specific Cell-Mediated Immune Reconstitution in Children with Advanced Human Immunodeficiency Virus Infection Receiving Highly Active Antiretroviral Therapy. Clinical Infectious Diseases, 2004, 39, 107-114.	5.8	19
132	Varicellaâ€Zoster Virus–Specific Cellâ€Mediated Immunity in HIVâ€Infected Children Receiving Highly Active Antiretroviral Therapy. Journal of Infectious Diseases, 2004, 190, 267-270.	4.0	24
133	Evaluation of R-Mix shell vials for the diagnosis of viral respiratory tract infections. Journal of Clinical Virology, 2004, 30, 100-105.	3.1	45
134	Development of Resistance to Acyclovir during Chronic Infection with the Oka Vaccine Strain of Varicellaâ€Zoster Virus, in an Immunosuppressed Child. Journal of Infectious Diseases, 2003, 188, 954-959.	4.0	134
135	Disseminated Varicella Infection Due to the Vaccine Strain of Varicellaâ€Zoster Virus, in a Patient with a Novel Deficiency in Natural Killer T Cells. Journal of Infectious Diseases, 2003, 188, 948-953.	4.0	162
136	Mutations Conferring Foscarnet Resistance in A Cohort of Patients with Acquired Immunodeficiency Syndrome and Cytomegalovirus Retinitis. Journal of Infectious Diseases, 2003, 187, 777-784.	4.0	87
137	Immunity to Human Immunodeficiency Virus (HIV) in Children with Chronic HIV Infection Receiving Highly Active Antiretroviral Therapy. Vaccine Journal, 2003, 10, 821-825.	3.1	15
138	Cytomegalovirus-specific IFN-γ production is associated with protection against cytomegalovirus reactivation in HIV-infected patients on highly active antiretroviral therapy. Aids, 2003, 17, 2445-2450.	2.2	26
139	Molecular Methods for Cytomegalovirus Surveillance in Bone Marrow Transplant Recipients. Journal of Clinical Microbiology, 2002, 40, 4203-4206.	3.9	30
140	The Role of Immune Reconstitution in Cytomegalovirus Infection. BioDrugs, 2002, 16, 89-95.	4.6	6
141	The value of polymerase chain reaction for the diagnosis of viral respiratory tract infections in lung transplant recipients. Journal of Clinical Virology, 2002, 25, 171-175.	3.1	75
142	Quantitative CSF PCR in Epstein-Barr virus infections of the central nervous system. Annals of Neurology, 2002, 52, 543-548.	5.3	145
143	Immunization of HIV-infected children with varicella vaccine. Journal of Pediatrics, 2001, 139, 305-310.	1.8	150
144	Recurrences of Cytomegalovirus Retinitis in a Human Immunodeficiency Virus-Infected Patient, Despite Potent Antiretroviral Therapy and Apparent Immune Reconstitution. Clinical Infectious Diseases, 2001, 32, 815-819.	5.8	77

#	Article	IF	CITATIONS
145	Acellular components ofChlamydia pneumoniae stimulate cytokine production in human blood mononuclear cells. European Journal of Immunology, 2000, 30, 541-549.	2.9	93
146	Viability and Functional Activity of Cryopreserved Mononuclear Cells. Vaccine Journal, 2000, 7, 714-716.	2.6	79
147	Shipment Impairs Lymphocyte Proliferative Responses to Microbial Antigens. Vaccine Journal, 2000, 7, 759-763.	2.6	41
148	Acellular components of Chlamydia pneumoniae stimulate cytokine production in human blood mononuclear cells. , 2000, 30, 541.		2
149	Cytokine Production in Varicellaâ€Zoster Virusâ€Stimulated Cultures of Human Blood Lymphocytes. Journal of Infectious Diseases, 1998, 178, S95-S98.	4.0	13
150	Effect of Shipment, Storage, Anticoagulant, and Cell Separation on Lymphocyte Proliferation Assays for Human Immunodeficiency Virus-Infected Patients. Vaccine Journal, 1998, 5, 804-807.	2.6	79
151	Improved detection of varicella zoster infection with a spin amplification shell vial technique and blind passage. Clinical and Diagnostic Virology, 1996, 5, 61-65.	1.7	12
152	Cryopreservation of Peripheral Blood Mononuclear Cells. , 0, , 263-268.		3
153	T-cell responses to SARS-CoV-2 in unexposed South African women. Gates Open Research, 0, 5, 150.	1.1	3
154	T-cell responses to SARS-CoV-2 in unexposed South African women. Gates Open Research, 0, 5, 150.	1.1	2